Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19302936 | ALLERGY TREATMENT | August 2025 | March 2026 | Allow | 7 | 1 | 0 | Yes | No |
| 19092641 | PROCESS OF PURIFICATION OF PROTEIN | March 2025 | December 2025 | Allow | 9 | 1 | 0 | No | No |
| 18977144 | NOVEL ANTIGEN BINDING MOLECULE FORMATS | December 2024 | April 2025 | Allow | 4 | 1 | 0 | No | No |
| 18664091 | BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLS | May 2024 | December 2024 | Allow | 7 | 1 | 0 | No | No |
| 18664070 | BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLS | May 2024 | March 2025 | Allow | 10 | 2 | 0 | No | No |
| 18640981 | NOVEL ANTIGEN BINDING MOLECULE FORMATS | April 2024 | February 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18609108 | MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND USES THEREOF | March 2024 | August 2025 | Allow | 17 | 1 | 0 | No | No |
| 18408386 | NUCLEIC ACIDS, VECTORS, AND CELLS THAT ENCODE ANTI-SP17 ANTIBODIES AND OTHER SP17 BINDING PROTEINS | January 2024 | October 2024 | Allow | 9 | 3 | 0 | No | No |
| 18395074 | IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF | December 2023 | April 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18545795 | METHODS OF TREATING ALLERGY USING ANTI-BET V 1 ANTIBODIES | December 2023 | October 2025 | Allow | 21 | 2 | 0 | No | No |
| 18494454 | VARIANT IgG FC POLYPEPTIDES AND USES THEREOF | October 2023 | March 2024 | Allow | 4 | 0 | 1 | No | No |
| 18491287 | FISH ALLERGY ANTIGEN | October 2023 | September 2025 | Allow | 23 | 1 | 0 | No | No |
| 18376135 | NANOEMULSION COMPOSITIONS FOR PREVENTING, SUPPRESSING OR ELIMINATING ALLERGIC AND INFLAMMATORY DISEASE | October 2023 | May 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18469961 | HLA BINDING VACCINE MOIETIES AND USES THEREOF | September 2023 | March 2025 | Allow | 18 | 2 | 0 | No | No |
| 18469947 | NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND BCMA VARIANTS WITH FC-ENGINEERING | September 2023 | August 2024 | Allow | 11 | 1 | 1 | No | No |
| 18244038 | COMPOSITION AND METHOD FOR REDUCING ALLERGIC RESPONSE | September 2023 | August 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18462987 | SOYBEAN ALLERGY ANTIGEN | September 2023 | June 2025 | Allow | 21 | 2 | 1 | No | No |
| 18457553 | AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE | August 2023 | December 2025 | Allow | 27 | 2 | 0 | No | No |
| 18232238 | HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF | August 2023 | February 2026 | Allow | 31 | 2 | 1 | No | No |
| 18344391 | AUTOIMMUNE SUPPRESSOR AND APPLICATION THEREOF | June 2023 | August 2025 | Allow | 26 | 2 | 1 | No | No |
| 18335995 | TRIVALENT TRISPECIFIC ANTIBODY CONSTRUCTS | June 2023 | August 2025 | Abandon | 26 | 0 | 1 | No | No |
| 18331280 | Antibodies that Specifically Bind PD-1 and Methods of Use | June 2023 | November 2024 | Allow | 18 | 1 | 0 | No | No |
| 18329443 | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 | June 2023 | September 2025 | Allow | 27 | 2 | 0 | No | No |
| 18318871 | NOVEL ANTIGEN BINDING MOLECULE FORMATS | May 2023 | December 2023 | Allow | 7 | 1 | 0 | No | No |
| 18308338 | IL-21 POLYPEPTIDES AND TARGETED CONSTRUCTS | April 2023 | December 2024 | Allow | 20 | 2 | 2 | Yes | No |
| 18303769 | CHIMERIC CANINE ANTI-CD20 ANTIBODY | April 2023 | September 2024 | Allow | 17 | 2 | 0 | No | No |
| 18192861 | COMPLEX-SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS AND ITS USE | March 2023 | January 2026 | Allow | 33 | 3 | 1 | No | No |
| 18246716 | CANINE ANTIBODY VARIANTS | March 2023 | October 2025 | Allow | 30 | 0 | 0 | No | No |
| 18246725 | FELINE ANTIBODY VARIANTS | March 2023 | October 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 18025985 | Pharmaceutical Composition For Allergen Specific Immunotherapy | March 2023 | March 2026 | Abandon | 36 | 0 | 1 | No | No |
| 18176678 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | March 2023 | March 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18176084 | Anti-B7-H4 Antibodies And Methods | February 2023 | January 2026 | Abandon | 35 | 2 | 1 | No | No |
| 18164442 | AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE | February 2023 | June 2023 | Allow | 5 | 0 | 0 | No | No |
| 18160745 | Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor | January 2023 | November 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18018444 | IL23 RECEPTOR SYNTHETIC CYTOKINES AND METHODS OF USE | January 2023 | April 2025 | Abandon | 26 | 3 | 1 | No | No |
| 18101601 | PD1-CD70 FUSION PROTEIN AND METHODS OF USE THEREOF | January 2023 | December 2024 | Abandon | 23 | 0 | 1 | No | No |
| 18006484 | IFNGR BINDING SYNTHETIC CYTOKINES AND METHODS OF USE | January 2023 | June 2024 | Allow | 16 | 2 | 1 | No | No |
| 18147789 | ALLERGY ANTIGEN AND EPITOPE FOR SAME | December 2022 | January 2026 | Allow | 37 | 3 | 1 | No | No |
| 18067504 | CD33-Binding Polypeptides and Uses Thereof | December 2022 | May 2024 | Allow | 17 | 0 | 0 | No | No |
| 18063896 | METHOD OF INDUCING TOLERANCE TO AN ALLERGEN | December 2022 | May 2025 | Abandon | 29 | 2 | 0 | No | No |
| 17980397 | COMBINATIONS FOR ALLERGY THERAPY | November 2022 | February 2024 | Abandon | 16 | 2 | 1 | No | No |
| 18050993 | Therapeutic Anti-IgE Antibodies and Methods and Compositions Thereof | October 2022 | April 2025 | Abandon | 29 | 0 | 1 | No | No |
| 17921355 | PREPARATION AND APPLICATION OF AN INTACT RECOMBINANT ANTIBODY SPECIFIC TO CLOTHIANIDIN BASED ON THE IDENTIFIED VARIABLE REGION SEQUENCE | October 2022 | November 2023 | Allow | 13 | 2 | 0 | No | No |
| 17996114 | DOSAGE UNITS AND REGIMEN, USES, METHODS OR FORMULATIONS OF COMPOSITIONS COMPRISING A RECOMBINANT PROTEIN COMPRISING INTERLEUKIN-12 AND AN ANTIBODY BINDING THE EXTRA-DOMAIN B OF FIBRONECTIN | October 2022 | August 2025 | Abandon | 34 | 5 | 0 | No | No |
| 17936739 | METHODS OF TREATMENT USING A VETERINARY MITE ALLERGEN EXTRACT | September 2022 | October 2025 | Abandon | 37 | 3 | 1 | No | No |
| 17933185 | MODIFYING BINDING MOLECULES TO MINIMIZE PRE-EXISITING INTERACTIONS | September 2022 | September 2025 | Allow | 36 | 2 | 1 | No | No |
| 17945504 | Immunotherapy For The Treatment Of Allergic Disease | September 2022 | September 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17891757 | MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAME | August 2022 | April 2025 | Allow | 32 | 2 | 0 | Yes | No |
| 17800837 | METHOD FOR TREATING ASTHMA OR ALLERGIC DISEASE | August 2022 | March 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17887144 | BETA-GLUCAN IMMUNOTHERAPIES AFFECTING THE IMMUNE MICROENVIRONMENT | August 2022 | September 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17877432 | ANTIBODIES THAT BIND HUMAN CANNABINOID 1 (CB1) RECEPTOR | July 2022 | May 2025 | Abandon | 34 | 2 | 0 | Yes | No |
| 17795075 | METHOD FOR PRODUCING COMPOSITION CONTAINING POLYPEPTIDE WITH SUPPRESSED COLORING | July 2022 | December 2025 | Allow | 41 | 1 | 0 | No | No |
| 17813985 | THERAPEUTIC INTERFERON ALPHA 1 PROTEINS | July 2022 | November 2025 | Allow | 40 | 3 | 0 | No | No |
| 17813578 | ANTI-GAL3 ANTIBODIES AND USES THEREOF | July 2022 | August 2025 | Allow | 37 | 2 | 1 | No | No |
| 17858112 | PROCESS FOR OBTAINING ANTIBODIES | July 2022 | December 2024 | Allow | 29 | 2 | 0 | No | No |
| 17607985 | METHOD FOR SELECTING BIOLOGICAL BINDING MOLECULES | July 2022 | December 2025 | Abandon | 49 | 1 | 0 | No | No |
| 17848808 | FC VARIANTS WITH REDUCED EFFECTOR FUNCTION | June 2022 | October 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17834237 | Anti-PD-1 Antibodies and Uses Thereof | June 2022 | October 2023 | Allow | 16 | 0 | 0 | Yes | No |
| 17752639 | METHODS OF ORAL IMMUNOTHERAPY | May 2022 | May 2025 | Allow | 35 | 2 | 1 | Yes | No |
| 17736859 | METHODS OF TREATING AN ALLERGY WITH ALLERGEN-SPECIFIC MONOCLONAL ANTIBODIES | May 2022 | March 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17714507 | ANTI-ALLERGEN ANTIBODIES | April 2022 | January 2025 | Allow | 34 | 1 | 0 | No | No |
| 17707243 | RECOMBINANT INTRAVENOUS IMMUNOGLOBULIN (RIVIG) COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND USE | March 2022 | June 2023 | Allow | 15 | 0 | 0 | Yes | No |
| 17697467 | Methods and Devices for the Treatment of Food Allergies | March 2022 | March 2026 | Allow | 48 | 4 | 0 | No | No |
| 17672571 | NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOF | February 2022 | January 2024 | Allow | 23 | 0 | 0 | Yes | No |
| 17648242 | METHODS OF TREATING KAWASAKI DISEASE | January 2022 | May 2024 | Allow | 28 | 1 | 0 | No | No |
| 17536667 | Peptides, Reagents And Methods For Detecting Food Allergy | November 2021 | October 2025 | Allow | 46 | 2 | 1 | Yes | Yes |
| 17595193 | SYSTEMIC ALLERGIC RESPONSE RISK ASSESSMENT IN PEANUT ORAL IMMUNOTHERAPY | November 2021 | September 2025 | Allow | 46 | 1 | 1 | No | No |
| 17510772 | PEANUT HYPOALLERGENIC FORMULATIONS FOR DETERMINING THE RISK OF ANAPHYLAXIS | October 2021 | May 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17604964 | METHOD FOR SEPARATION OF ANTIBODIES OR ANTIBODY FRAGMENTS BEING DEVOID OF AN FC REGION CAPABLE OF BINDING TO PROTEIN A | October 2021 | October 2025 | Allow | 48 | 3 | 0 | No | No |
| 17501305 | IMMUNE MODULATION | October 2021 | August 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17500794 | ANTIBODIES TO OXIDATION-SPECIFIC EPITOPES | October 2021 | March 2025 | Allow | 41 | 2 | 0 | Yes | No |
| 17500418 | HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF | October 2021 | November 2024 | Allow | 37 | 1 | 1 | No | No |
| 17498512 | TREATMENT OF CANCER USING A CEA CD3 BISPECIFIC ANTIBODY AND A WNT SIGNALING INHIBITOR | October 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17601628 | COMBINATION OF SYNTHETIC PEPTIDES WITH AFFINITY TO THE TGF-ß RECEPTOR AND WITH AFFINITY TO THE IL-10 RECEPTOR, PHARMACEUTICAL COMPOSITION AND THEIR USE AS IMMUNOMODULATORS IN THE TREATMENT OF AUTOIMMUNE, INFLAMMATORY OR ALLERGIC DISEASES | October 2021 | June 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17601359 | METHODS OF DEPLETING DISEASE CAUSING AGENTS VIA ANTIBODY TARGETED PHAGOCYTOSIS | October 2021 | December 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17478310 | MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAME | September 2021 | September 2025 | Abandon | 48 | 3 | 0 | Yes | No |
| 17438702 | Manufacturing Methods for Producing Anti-TNF Antibody Compositions | September 2021 | February 2024 | Allow | 29 | 1 | 0 | No | No |
| 17471804 | ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF | September 2021 | December 2023 | Allow | 27 | 1 | 0 | No | No |
| 17438209 | NON-CONSENSUS GLYCOSYLATION OF BISPECIFIC ANTIBODIES | September 2021 | November 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17432705 | MODIFIED FC FRAGMENT, ANTIBODY COMPRISING SAME, AND APPLICATION THEREOF | August 2021 | February 2025 | Allow | 42 | 5 | 1 | Yes | No |
| 17399871 | CONDITIONING REGIMENS AND METHODS FOR INDUCING MIXED CHIMERISM | August 2021 | January 2024 | Allow | 29 | 2 | 0 | No | No |
| 17394506 | ADMINISTRATION OF VACCINES TO SITES OF TEMPORALLY INDUCED CELL-MEDIATED HYPERSENSITIVITY REACTIONS, TO FACILITATE THE DEVELOPMENT OF PROTECTIVE SENSITIZATION AGAINST INFECTIOUS DISEASES AND CANCERS | August 2021 | February 2026 | Abandon | 55 | 3 | 1 | Yes | No |
| 17384628 | MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAME | July 2021 | January 2025 | Abandon | 42 | 2 | 1 | Yes | No |
| 17383374 | METHODS OF DETECTING MARKERS FOR INFLAMMATORY CONDITIONS AND FOOD SENSITIVITY IN COMPANION ANIMALS | July 2021 | January 2026 | Allow | 54 | 4 | 1 | Yes | No |
| 17374519 | NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF | July 2021 | December 2023 | Allow | 29 | 1 | 0 | No | No |
| 17422222 | METHODS OF INTRODUCING FOOD ALLERGENS | July 2021 | December 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17368366 | NANOEMULSION COMPOSITIONS FOR PREVENTING, SUPPRESSING OR ELIMINATING ALLERGIC AND INFLAMMATORY DISEASE | July 2021 | June 2023 | Allow | 24 | 1 | 0 | No | No |
| 17364299 | METHODS OF TREATING ALLERGY USING ANTI-BET V 1 ANTIBODIES | June 2021 | September 2023 | Allow | 27 | 2 | 0 | No | No |
| 17414265 | ANTIGEN BINDING FORMATS FOR RECEPTOR COMPLEXES | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17298104 | METHODS FOR MAKING MIXED ALLERGEN COMPOSITIONS | May 2021 | September 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17298246 | SINGLE DOMAIN ANTIBODIES AGAINST CLL-1 | May 2021 | December 2025 | Allow | 55 | 2 | 1 | No | No |
| 17297796 | ANTIBODY COMPRISING A GLUTAMINE-CONTAINING LIGHT CHAIN C-TERMINAL EXTENSION, CONJUGATES THEREOF, AND METHODS AND USES | May 2021 | December 2024 | Allow | 43 | 1 | 0 | No | No |
| 17303268 | METHODS OF TREATING INFLAMMATORY DISEASES BY BLOCKING GALECTIN-3 | May 2021 | December 2024 | Allow | 43 | 4 | 1 | Yes | No |
| 17325268 | MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND USES THEREOF | May 2021 | December 2023 | Allow | 31 | 0 | 1 | No | No |
| 17315547 | VARIABLE REGIONS FOR NKP46 BINDING PROTEINS | May 2021 | September 2023 | Allow | 29 | 0 | 1 | Yes | No |
| 17313738 | Reduction of viral disease transmission by avian antibodies | May 2021 | November 2025 | Abandon | 54 | 2 | 1 | No | Yes |
| 17243372 | ANTI-PD-L1 ANTIBODIES | April 2021 | September 2024 | Allow | 40 | 2 | 1 | No | No |
| 17285884 | RAPID CELL ISOLATION AND RECOVERY USING HOLLOW GLASS MICROSPHERES COATED WITH BIODEGRADABLE NANOSTRUCTURED FILMS | April 2021 | June 2025 | Allow | 50 | 2 | 1 | No | No |
| 17231544 | MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAME | April 2021 | January 2025 | Abandon | 45 | 2 | 1 | Yes | No |
| 17282781 | HER2-BINDING TETRAMERIC POLYPEPTIDES | April 2021 | June 2025 | Abandon | 50 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ROONEY, NORA MAUREEN.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 41.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner ROONEY, NORA MAUREEN works in Art Unit 1641 and has examined 199 patent applications in our dataset. With an allowance rate of 80.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 45 months.
Examiner ROONEY, NORA MAUREEN's allowance rate of 80.9% places them in the 51% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by ROONEY, NORA MAUREEN receive 2.66 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by ROONEY, NORA MAUREEN is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +13.5% benefit to allowance rate for applications examined by ROONEY, NORA MAUREEN. This interview benefit is in the 51% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 24.0% of applications are subsequently allowed. This success rate is in the 34% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 39.8% of cases where such amendments are filed. This entry rate is in the 61% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 82.4% of appeals filed. This is in the 75% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 81.6% are granted (fully or in part). This grant rate is in the 85% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 9.5% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.7% of allowed cases (in the 76% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.